Heparin for patients with coronavirus disease 2019 and hypercoagulation complications: A cohort study.

ABSTRACT:

Background

Thrombotic complications of coronavirus disease 2019 (COVID-19) are a worrisome aspect of the disease due to their high incidence in critically ill patients and their poor clinical outcomes. The aim of this study was to compare the effectiveness of unfractionated heparin (UFH) and low molecular weight heparin (LMWH) (fondaparinux) in hospitalized COVID-19 patients with hypercoagulable complications.

Material and methods

The study design used a retrospective cohort approach incorporating pre- and post-tests via secondary data extracted from the medical records of inpatients with confirmed COVID-19.

Results

Among the 98 individuals studied (52% women; 30.6% at >60 years of age), 35 patients received UFH, while the remaining 63 patients received LMWH (fondapar

SUBMITTER: Fachri M 

PROVIDER: S-EPMC9238275 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature